Diacerein Cream for Adults With Plaque Psoriasis
Tests diacerein cream against placebo cream in adults with psoriasis vulgaris.
Plain-language title generated from the registry record
Registry title: Topical Diacerein in Psoriasis Vulgaris
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 4
Where in Egypt
- Kasr Al-Ainy Psoriasis UnitCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alaa Ashraf Muhammad Helal
- Trial code
- NCT07352306
- Record updated
- 22 October 2026
- Original description
The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the placebo group.Read full original descriptionShow less
The Efficacy of Topical Diacerein Cream in Patients With Psoriasis Vulgaris
The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the placebo group.
Participants will:
Be assigned to receive topical diacerein 1% or placebo twice daily for a treatment period of 2 months.
Attend follow-up visits at Weeks 2, 4, 6, and 8. Undergo an additional evaluation one month after treatment cessation.
Inclusion: Age ≥18 years old of both genders; Patients with mild chronic plaque psoriasis body surface area (BSA < 10%) along with Psoriasis Area and Severity Index (PASI) score of < 10, and/or Dermatology Life Quality Index (DLQI) score of <10.
Exclusion: Documented hypersensitivity or idiosyncratic reaction to the investigational product or any excipients contained within the cream formulation; Intake of anti-psoriatic systemic therapy within the last 3 months, or topical treatments within the last 2 weeks; Patients with pustular psoriasis; Pregnant and breast-feeding individuals; Patients with psoriatic arthritis.